Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense  

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, has been selected to provide its RENASYS TOUCH Negative Pressure Wound Therapy (NPWT) Systems under a single award, 10-year* contract for up to $75 million by the U.S. Department of Defense (DoD) through the Defense Logistics Agency (DLA).

The RENASYS TOUCH NPWT System demonstrated clinical efficacy,1,2,3,4 and operational fitness including portability,2 an intuitive interface,5,6,7 and the ability to provide a range of therapy modes, set points and cycle times that allow individualized patient care. The system will support military medical providers to administer therapy through prolonged casualty care, first surgical intervention, aeromedical transport and definitive care in military treatment facilities. RENASYS TOUCH NPWT is manufactured in the United States.  


[img]http://phpstack-1214942-4313335.cloudwaysapps.com/api/ImageRender/DownloadFile?resourceId=5147e1d8-025e-4b20-8c3a-1ad3c716e8eb&size=0[/img]

“Future conflicts will be more difficult and complex. This implies medical devices and treatments will need to be simplified and more intuitive to be used farther forward by a wide range of providers. RENASYS TOUCH NPWT will provide that simplified negative pressure wound therapy solution to the military care continuum for warfighters who need it most,” said Dennis Lyons, MSG (ret), SO-ATP and Sr. Director Military & Federal Health for Smith+Nephew. 

In 2024, Smith+Nephew announced the entry into a Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) to partner to transform wound and burn care across the military care continuum.8 

Smith+Nephew has a longstanding history of supporting military medical needs beginning with the First Field Dressing dating back to World War I. This legacy continues to evolve, meeting the growing needs of both civilian and military healthcare providers and patients. Today, our commitment to innovation in wound care continues through an extensive Advanced Wound Management portfolio designed to meet complex clinical needs and help healthcare providers reduce human and economic consequences of wounds.2

 - ends –

 

 

Media Enquiries

Dave Snyder          +1 (978) 749-1440 

Smith+Nephew      david.snyder@smith-nephew.com

 

 * 5 years plus 5 one-year options

 

References

Smith+Nephew 2018. Results Sheet for the RENASYS TOUCH PCS Outcomes in Flaps. Internal Report. ST924A. Forlee M, Zyl LV, Louw H, Nel J, Fourie N, Hartley R. A randomised controlled trial to compare the clinical efficacy and acceptability of adjustable intermittent and continuous Negative Pressure Wound Therapy (NPWT) in a new portable NPWT system. Poster presented at: European Wound Management Association (EWMA)2018; Krakow, Poland. Wounds International 2020. Retrospective chronic and postsurgical wound case series: Understanding RENASYS TOUCH. London, UK. Frear CC, Cuttle L, McPhail M, Chatfield MD, Kimble RM, Griffin BR. Randomized clinical trial of negative pressure wound therapy as an adjunctive treatment for small-area thermal burns in children. BJS. 2020;107(13):1741 - 1750. Forlee M, Nel J, Richardson J, Rossington A, Cockwill J, Smith J. An interim analysis of device functionality and usability of RENASYS™ TOUCH - a new portable Negative Pressure Wound Therapy (NPWT) system. Poster presented at: Wounds UK2016; Harrogate, UK. Smith+Nephew 2016. Smith and Nephew’s RENASYS Touch Device Features – Software features. Internal Report. DS/16/179/R. Smith+Nephew 2016. Smith and Nephew’s RENASYS Touch Device – User Validation. Internal Report. DS/16/174/R. https://www.smith-nephew.com/en/news/2024/02/28/20240228-smith-nephew-and-u-s-army-institute-of-surgical-research-to-engage

 

 About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

 

Forward-looking StatementsThis document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

 

◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.


Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense  


THỦ THUẬT HAY

Hướng dẫn thay đổi hình nền đẹp cho máy tính

Hãy trang bị cho máy tính của mình một bộ sưu tập hình nền độc đáo và tuyệt đẹp để thay đổi diện mạo cho nó. Đồng thời, tự tạo ra cho mình niềm vui nhỏ trong cuộc sống thường ngày.

Hướng dẫn cách sử dụng Cốc Cốc Map trên điện thoại

Những dữ liệu của Cốc Cốc Map luôn được cập nhật liên tục với những địa điểm mới, những nhận xét và đánh giá của người dùng tới những địa điểm đó, để những tính năng trên có thể hoạt động, bạn cần đăng nhập vào Cốc Cốc

Cách tính diện tích hình thang vuông, cân, khi biết độ dài 4 cạnh, công thức tính

Hình thang không còn quá xa lạ gì với chúng ta khi mà hình này được gặp khá nhiều trong cuộc sống, khi còn đi học chúng ta cũng đã có khá nhiều bài tập liên quan tới hình thang. Nếu như việc tính chu vi hình thang thì

Các mẹo giúp bạn tận dụng toàn bộ tính năng hay ho trên Galaxy Note FE (Phần 2 )

Thư mục an toàn là một tính năng được tạo ra nhằm hỗ trợ người sử dụng bảo vệ những thông tin cá nhân quan trọng.

Hướng dẫn in nội dung trên iPhone, iPad

Nhiều người dùng khi muốn in nội dung viết hay tải về trên iPhone, iPad thường phải copy dữ liệu ra máy tính trước đó. Tuy nhiên có một thủ thuật giúp bạn in nội dung trên iPhone, iPad trực tiếp mà không cần sử dụng

ĐÁNH GIÁ NHANH

Đánh giá Lenovo ThinkPad L380: Sức hút kỳ lạ dành cho chiếc Laptop tầm trung

Với mức giá khoảng 24 triệu đồng cho bản Core i7 và 18,5 triệu đồng cho bản Core i5, rõ ràng ThinkPad L380 đang hướng đến đối tượng người dùng yêu cầu cao về sự gọn nhẹ, di động nhưng vẫn phải đảm hiệu năng tốt cùng

Trên tay Vivo Y33s – Smartphone hơn 5 triệu, camera 50MP

Vivo Y33s là bản kế nhiệm của Vivo Y31 2021 được nâng cấp và cải tiến rất nhiều. Camera, vi xử lý, tuổi thọ pin và đặc biệt giá bán chỉ dưới 6 triệu đồng. Bài viết trên tay vivo Y33s dưới đây sẽ giúp bạn hiểu rõ hơn về

Đánh giá nhanh Surface Book 2: bản lề chắc chắn hơn, cấu hình tốt hơn

Cấu hình đã mạnh mẽ hơn và được việc hơn nhờ thế hệ vi xử lý Kaby Lake Refresh - lần đầu CPU dòng U có 4 nhân 8 luồng, thêm vào đó là GPU rời thế hệ Pascal.